摘要
目的 探讨大麻二酚对小鼠肾缺血再灌注损伤的保护作用。方法 将32只8周龄的WTC57BL/6雄性小鼠分为假手术组,模型组,大麻二酚5、10 mg·kg^(-1)组(均n=8)。采用无创动脉夹夹闭双侧小鼠肾蒂缺血35 min后再灌注24 h,建立小鼠肾缺血再灌注损伤模型。术后24 h检测血清肌酐(Scr)、尿素氮(BUN)、白细胞介素(IL)-1β、肿瘤坏死因子(TNF)-α水平,检测肾组织超氧化物歧化酶(SOD)水平和丙二醛(MDA)含量。光镜下观察肾组织病理学改变。结果 与假手术组相比,模型组小鼠Scr、BUN、IL-1β、TNF-α水平和MDA含量及肾脏病理损伤评分均升高(P <0.05),SOD水平降低(P <0.05)。与模型组相比,大麻二酚5、10 mg·kg^(-1)组Scr、BUN、IL-1β、TNF-α水平和MDA含量以及肾脏病理评分显著降低(P <0.05),SOD水平升高(P <0.05)。结论 大麻二酚可减轻小鼠肾缺血再灌注损伤,其保护作用可能与减轻炎症反应、抑制氧化应激有关。
AIM To investigate the protective effect of cannabidiol on renal ischemia-reperfusion injury in mice.METHODS Thirty-two 8-week-old male WTC57BL/6 mice were randomly divided into sham group,model group,cannabidiol 5 and 10 mg·kg^(-1)group,with 8 mice in each group.The model of renal ischemia-reperfusion injury in mice was established by clamping bilateral renal pedicles through non-invasive artery clamp for 35 minutes and then reperfusion for 24 hours.Serum creatinine(Scr),blood urea nitrogen(BUN),interleukin(IL)-1β,and tumor necrosis factor(TNF)-αlevels were measured 24 hours after operation.Superoxide dismutase(SOD)level and malondialdehyde(MDA)contents in renal tissue were detected.The pathological changes of renal tissue were observed under light microscope.RESULTS Compared with the sham group,the serum levels of Scr,BUN,IL-1β,TNF-α,MDA contents and renal pathological damage score in the model group were increased(P<0.05),and the level of SOD was decreased(P<0.05).Compared with the model group,the serum levels of Scr,BUN,IL-1β,TNF-α,MDA and renal pathological scores decreased significantly in the cannabidiol 5 and 10 mg·kg^(-1)groups(P<0.05),while levels of SOD increased significantly(P<0.05).CONCLUSION Cannabidiol can alleviate renal ischemia-reperfusion injury in mice,and its protective effect may be related to reducing inflammatory response and inhibiting oxidative stress.
作者
赵朋涛
闫聚瀚
闫晓冬
刘鑫
李向东
ZHAO Peng-tao;YAN Ju-han;YAN Xiao-dong;LIU Xin;LI Xiang-dong(Graduate School,Hebei North University,Zhangjiakou HEBEI 075000,China;The First Affliated Hospital of Hebei NorthUniversity,Zhangjiakou HEBEI075000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2023年第7期457-461,共5页
Chinese Journal of New Drugs and Clinical Remedies